Robert John Hoyer
Title | Asst Professor-Clinical |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
Phone | 719/365-6568 |
---|
|
|
|
Biography Georgetown University, Washington, DC | B.S. | 5/1998 | Biology | Georgetown University School of Medicine, Washington, DC | M.D. | 5/2002 | | Mayo Graduate School of Medicine, Rochester, MN | | 6/2005 | Internal Medicine | Mayo Graduate School of Medicine, Rochester, MN | | 6/2008 | Hematology/Oncology |
1998 | Cum Laude, Georgetown University | 1998 | Sigma Xi Scientific Research Society, Georgetown University | 2013 - 2017 | "Top Doc" (Peer Nominated), Colorado Springs Style Magazine |
Overview I currently serve as director of Memorial Cancer Center and have served as the lead investigator at Memorial for multiple cooperative group studies. In 2017 Memorial accrued 103 patients to clinical trials. Our group sees between 150-200 new patients per month. We have prospective tumor-boards and multidisciplinary clinics to facilitate identification of patients who may be eligible for research studies.
On October 1, 2012 Memorial Health System became a part of the University of Colorado Health system. In 2013, Memorial Cancer Center became a Lead Academic Participating Site (LAPS) within the National Clinical Trials Network (NCTN). Memorial Hospital has had a strong track record of cooperative group research collaboration and performance which has increased during the last 4 years as an integral part of the University of Colorado LAPS site. We look forward to the continued integration of clinical trials across the entire University of Colorado Health System and University of Colorado Cancer Center.
I have developed expertise in gastrointestinal, thoracic and neuro-oncology and regularly staff our weekly multidisciplinary clinics. I serve as Medical Director for Oncology Research at Memorial and meet regularly with investigators, the research team and UCHealth research administration.
Bibliographic
-
Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2024 Jan; 5(1):210. PMID: 38200246.
-
Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. Author Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2023 Jan; 4(1):148. PMID: 36577897.
-
Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2022 11; 3(11):1300-1317. PMID: 36434392.
-
Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol. 2019 10 01; 30(10):1613-1621. PMID: 31504118.
-
Hoyer RJ, Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol. 2007 May; 82(5):409-13. PMID: 17326106.
-
LeMarbre G, Schinstock C, Hoyer R, Krook J, Tefferi A. Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate. Leuk Res. 2007 Mar; 31(3):414-5. PMID: 17010430.
-
Hoyer RJ, Arora AS, Baron TH. Complications after traction removal of direct percutaneous endoscopic jejunostomy: three case reports. Gastrointest Endosc. 2005 Nov; 62(5):802-5. PMID: 16246705.
-
Ellis JM, Hoyer RJ, Costello CN, Mshana RN, Quakyi IA, Mshana MN, Diaby B, Traore M, Johnson AH, Hurley CK. HLA-B allele frequencies in C?te d'Ivoire defined by direct DNA sequencing: identification of HLA-B*1405, B*4410, and B*5302. Tissue Antigens. 2001 Apr; 57(4):339-43. PMID: 11380943.
-
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000 Dec 01; 18(23):3964-73. PMID: 11099326.
-
Lin YS, Hoyer RJ, Tang TF, Ng J, Hartzmann RJ, Hurley CK. Detection of four novel alleles: DRB1*1130, DRB1*13072, DRB1*1315 and DRB1*1331. Tissue Antigens. 2000 Jan; 55(1):92-6. PMID: 10703621.
-
Hurley CK, Steiner N, Kosman C, Mitton W, Koester R, Bei M, Bush J, McCormack J, Hahn A, Henson V, Hoyer R, Wade JA, Hartzman RJ, Ng J. Novel HLA-A and HLA-B alleles. Tissue Antigens. 1998 Jul; 52(1):84-7. PMID: 9714480.
-
Hoyer RJ, Bratlie A, Schreuder GM, Hurley CK. Characterization of a novel HLA-B allele, B*0804, in a Norwegian family. Tissue Antigens. 1997 Sep; 50(3):308-10. PMID: 9331954.
-
Hurley CK, Steiner N, Hoyer RJ, Menchaca E, Mitton W, Simonis T, Hartzman RJ, Johnson AH, Ng J. Novel HLA-B alleles, B*8201, B*3515 and B*5106, add to the complexity of serologic identification of HLA types. Tissue Antigens. 1996 Mar; 47(3):179-87. PMID: 8740766.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1996 | 1 | 1997 | 1 | 1998 | 1 | 2000 | 2 | 2001 | 1 | 2005 | 1 | 2006 | 1 | 2007 | 1 | 2019 | 1 | 2022 | 1 | 2023 | 1 | 2024 | 1 |
To return to the timeline, click here.
|
Hoyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|